Previous Close | 15.98 |
Open | 16.07 |
Bid | 13.67 x 800 |
Ask | 19.26 x 900 |
Day's Range | 15.61 - 16.55 |
52 Week Range | 11.25 - 60.66 |
Volume | |
Avg. Volume | 282,777 |
Market Cap | 420.235M |
Beta (5Y Monthly) | 2.24 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.44 |
Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 69.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for NOTV
Insiders who bought US$1.7m worth of Inotiv, Inc. ( NASDAQ:NOTV ) stock in the last year recovered part of their losses...
WEST LAFAYETTE, Ind., May 16, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences: UBS Gl
WEST LAFAYETTE, Ind., May 12, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2022”) and six months (“H1 FY 2022”) ended March 31, 2022. Q2 FY 2022 Highlights Revenue grew 646.3% to $140.3 million, from $18.8 mi